德意志银行维持联合健康集团（UNH.US）"持有"评级，目标价467美元，对应2027年每股收益（EPS）的20倍。报告聚焦2027年星级评定（Star Ratings）走弱可能压制2028年质量奖金支付的风险：UNH目前约81%的Medicare Advantage（MA）会员位于4星及以上合约，在大型管理式医疗保险公司中处于较高水平，其中最大合约H2001约占MA会员的24%，第二大合约H5253约占12%，且约28%会员落在恰好4.0星的合约上。Plan Preview 2显示约54%的沿用指标切分点上移，其中约三分之二至70%的HEDIS指标门槛提高，即便部分质量指标改善，整体星级仍可能与2026年大体持平。管理层表示四项药房指标全部改善、12项HEDIS指标中10项改善，但福利调整导致CAHPS指标回落。若H2001失去奖金支付星级，或带来2028年3%至5%的EPS逆风；
Deutsche Bank maintains a Hold rating on UnitedHealth Group (UNH.US) with a price target of $467, representing 20x its 2027 EPS estimate. Plan Preview 2 Posing Risk to UNH's 2028 Earnings Recovery: UNH shares have remained soft since Plan Preview 2 became available in early September as investors increasingly focused on the risk that weaker 2027 Star Ratings could pressure 2028 quality bonus payments. UNH currently has around 81% of MA enrollment in 4+ Star contracts, among the highest levels across the large MCOs. Plan Preview 2 analyses suggested the Stars backdrop remains challenging, with ~54% of returning measure cut points moving higher, including roughly two-thirds to 70% of HEDIS measures. Despite improvement in some underlying quality metrics, overall Star Ratings could still remain broadly similar to 2026 given the tougher relative thresholds. UNH management commented that the company improved all four pharmacy measures and 10 of 12 HEDIS measures, with the other two holding